PrimeCare® Integrates MedTek21® to Offer Facility-based Genomic Testing

MedTek21 v4.0 Expands Advanced Genomic Reporting, Alerts, and Real-time Connectivity to More Health Information Systems
July 25, 2018

PrimeCare® Integrates MedTek21® to Offer Facility-based Genomic Testing

download

(Anacortes, WA – June 3, 2019) Integra is teaming with MedTek21 to provide long-term care pharmacies and the facilities they serve with actionable genomic testing. This partnership further enables long-term care pharmacists to improve care and lower costs for their patients by incorporating drug-to-gene alerting within the existing pharmacy workflow.

“Patients react to medications differently,” said Tabb Stringer, Vice President of Product Management for Integra. “By interfacing MedTek21 with PrimeCare, it’s easier than ever for pharmacists to utilize insights from clinical-grade genomic testing to help optimize prescriptions and dosing for every patient.”

MedTek21’s system continuously identifies patients with chronic diseases or conditions who would benefit from genomic testing. Once a simple cheek swab is taken and analyzed by a clinical diagnostic lab, results are delivered through MedTek21 with clear and actionable insights. These results allow healthcare providers to assess the optimal selection and dosing of medications and can also be used in existing consulting pharmacy processes, such as resident medication reviews.

“Our goal at MedTek21 is to empower pharmacists as they play an ever-increasing role in the delivery of actionable, value-based care,” said Dave Copas, co-founder of MedTek21. “Integrating our products within PrimeCare enhances the ease of access to pharmacogenomics and personalized medication management for long-term care pharmacies and facilities across the country.”
Reactions to prescription drugs are a major cause of hospital admissions, emergency room visits, and other negative outcomes. Complications from genetic variations play a role in medication-related adverse events and poor therapeutic response, and the FDA even maintains its own database of medications with on-label guidance based on personalized variations in drug metabolism. Through the science of drug-to-gene monitoring, those risks can be identified and mitigated.

“Genomic testing is an actionable component in the future of personalized healthcare,” Stringer added. “The results gathered from the testing can help pharmacies be proactive in providing better care tailored directly at the patient level. They can also lead to lower healthcare costs for the patient and the pharmacy.”

 

About Integra: Integra designs software tailored exclusively to help pharmacists offer world-class care that improves patient outcomes and lifestyles. Integra offers PrimeCare, the state-of-the-art pharmacy operation system for long-term care pharmacy operations, DocuTrack®, WebConnect®, DeliveryTrack®, Logix®, and Mevesi®. Integra is the premiere partner in the long-term care, institutional, and closed-door pharmacy marketplace. Integra is part of Smith Technologies, LLC, a subsidiary of the J M Smith Corporation, one of the largest privately held companies in South Carolina. For additional information about Integra and the products and services it provides, visit www.integragroup.com or call 866.257.4279.

About MedTek21: MedTek21 is a real-time population health and medication risk management platform that brings personalized drug-to-gene monitoring to every patient. The Company’s software-based platform works alongside existing medical record systems to continuously monitor, proactively identify, and help remediate potential medication risks. MedTek21’s medication risk alerting, proactive drug lookup tools, actionable reporting engine, and mobile-based user applications provide patients, pharmacists, and care providers with better real-time decision making. For more information on the Company, please visit www.MedTek21.com.